{"id":534684,"date":"2010-04-19T13:53:10","date_gmt":"2010-04-19T17:53:10","guid":{"rendered":"tag:www.hepatitis-central.com,2010:\/mt\/\/1.809"},"modified":"2010-04-19T13:58:59","modified_gmt":"2010-04-19T17:58:59","slug":"early-hcv-study-outcome-psi-7977","status":"publish","type":"post","link":"https:\/\/mereja.media\/index\/534684","title":{"rendered":"Early HCV Study Outcome: PSI-7977"},"content":{"rendered":"<p>Learn about the mid-trial results of PSI-7977&#8217;s effectiveness against Hepatitis C.<\/p>\n<p>Pharmasset jumps on hepatitis C study results<\/p>\n<p>PRINCETON, N.J.<\/p>\n<p>Pharmasset Inc. on Thursday reported promising early results from a clinical trial of a hepatitis C drug candidate.<\/p>\n<p>The company is testing a drug candidate called PSI-7977. In the midstage trial, a group of 63 hepatitis C patients are being treated with a combination of PSI-7977 and two older drugs, Pegasys and Copegus, or Pegasys and Copegus alone. None of the patients have received any previous treatment for the disease.<\/p>\n<p>Continue reading this entire article:<br \/>\n<a href=\"http:\/\/www.businessweek.com\/ap\/financialnews\/D9F3JTC00.htm\">http:\/\/www.businessweek.com\/ap\/financialnews\/D9F3JTC00.htm<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Learn about the mid-trial results of PSI-7977&#8217;s effectiveness against Hepatitis C. Pharmasset jumps on hepatitis C study results PRINCETON, N.J. Pharmasset Inc. on Thursday reported promising early results from a clinical trial of a hepatitis C drug candidate. The company is testing a drug candidate called PSI-7977. In the midstage trial, a group of 63 [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-534684","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/534684","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/comments?post=534684"}],"version-history":[{"count":0,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/534684\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/media?parent=534684"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/categories?post=534684"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/tags?post=534684"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}